A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in
comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after
administration of XP21279/Carbidopa and Sinemet and to explore exposure-response
relationships in a subset of subjects.
Phase:
Phase 2
Details
Lead Sponsor:
XenoPort, Inc.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa